Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis.

Molecular Oncology
Monica HellesøyBjorn Tore Gjertsen

Abstract

Incidence, molecular presentation and outcome of acute myeloid leukaemia (AML) are influenced by sex, but little attention has been directed at untangling sex-related molecular and phenotypic differences between female and male patients. While increased incidence and poor risk are generally associated with a male phenotype, the poor prognostic FLT3 internal tandem duplication (FLT3-ITD) mutation and co-mutations with NPM1 and DNMT3A are overrepresented in female AML. Here, we have investigated the relationship between sex and FLT3-ITD mutation status by comparing clinical data, mutational profiles, gene expression and ex vivo drug sensitivity in four cohorts: Beat AML, LAML-TCGA and two independent HOVON/SAKK cohorts, comprising 1755 AML patients in total. We found prevalent sex-associated molecular differences. Co-occurrence of FLT3-ITD, NPM1 and DNMT3A mutations was overrepresented in females, while males with FLT3-ITDs were characterized by additional mutations in RNA splicing and epigenetic modifier genes. We observed diverging expression of multiple leukaemia-associated genes as well as discrepant ex vivo drug responses, suggestive of discrete functional properties. Importantly, significant prognostication was observed onl...Continue Reading

References

Dec 13, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B LöwenbergW L van Putten
Jul 27, 2001·Molecular Human Reproduction·Y OkamuraM Fukumoto
Aug 30, 2001·Nature Immunology·C C Whitacre
Aug 30, 2002·British Journal of Haematology·Ray A CartwrightAnthony V Moorman
Aug 22, 2003·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Mar 18, 2011·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collab
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Oct 5, 2014·Journal of Hematology & Oncology·Sanam LoghaviJoseph D Khoury
Jan 1, 2015·Blood·R Coleman LindsleyBenjamin L Ebert
Jan 22, 2015·Nucleic Acids Research·Matthew E RitchieGordon K Smyth
Jun 13, 2015·Science Translational Medicine·Yiting LimWilliam Matsui
Oct 31, 2015·Journal of Cellular and Molecular Medicine·Ahmed Abdelbaset-IsmailMariusz Z Ratajczak
Jun 12, 2016·Blood·Klaus H MetzelerUNKNOWN AMLCG Study Group
Jun 20, 2016·Clinical Drug Investigation·Ignacio SegarraEduardo L Mariño
Aug 23, 2016·Nature Reviews. Immunology·Sabra L Klein, Katie L Flanagan
Nov 4, 2016·Physiological Reviews·Vera Regitz-Zagrosek, Georgios Kararigas
Jan 5, 2017·Blood·Bob LöwenbergUNKNOWN Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
Feb 28, 2017·Frontiers in Immunology·Sophie LaffontJean-Charles Guéry
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
Dec 10, 2017·Hematology·Rodrigo T Calado, Diego V Clé
Jul 28, 2018·Advances in Experimental Medicine and Biology·Chrisandra L ShufeltVirginia M Miller
Oct 20, 2018·Nature·Jeffrey W TynerBrian J Druker
Oct 21, 2018·Blood Advances·Masahiro SakaguchiKoiti Inokuchi
Dec 16, 2018·Theriogenology·Woo-Sung KwonMyung-Geol Pang

❮ Previous
Next ❯

Citations

Sep 3, 2021·Molecular Oncology·Ruzhica Bogeska

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.